IP

Immunoprecise Antibodies LtdNASDAQ IPA Stock Report

Last reporting period 31 Jul, 2024

Updated 25 Nov, 2024

Last price

Market cap $B

0.018

Micro

Exchange

XNAS - Nasdaq

IPA Stock Analysis

IP

Uncovered

Immunoprecise Antibodies Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-44/100

Low score

Market cap $B

0.018

Dividend yield

Shares outstanding

24.935 B

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 85 full-time employees. The firm offers species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program- platforms. The company leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its technologies in bio platform-based antibody discovery. The company offers a selection of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma licensing for research purposes. Its services include specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners. The firm offers support to its partners, including rapid multi-omic analysis, customized project design, target identification and preparation, an on-site vivarium, and others.

View Section: Eyestock Rating